Health Care • Biotechnology: Pharmaceutical Preparations
$43.20 ▼ -0.80
(-1.82%)
MKT CAP: $2.05B • VOL: 475.3K
52W L $18 52W H $51
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$36
MEDIAN
$48
MEAN
$49
HIGH
$59
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SEPN TAPE
SEPN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $52.27 | $49.68 | 2025-02-14 | $39.31 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $54.43 | $50.98 | 2025-02-06 | $40.61 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $49.25 | $47.52 | 2025-01-29 | $41.47 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $44.06 | — | 2025-01-17 | $42.34 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $38.02 | $41.04 | 2025-01-09 | $38.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $51.41 | $44.93 | 2024-12-18 | $37.58 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $41.90 | $43.63 | 2024-12-04 | $40.18 | -4.3% | 48% | C |